Extraordinary General Meeting 2019
Västra Trädgårdsgatan 15, Stockholm, Sweden.
Upcoming events
Webcast -- update from the ODAC meeting, Sep 22
14:00 CET
September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.